Filing Details
- Accession Number:
- 0001209191-19-024176
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-04-09 19:00:38
- Reporting Period:
- 2019-04-05
- Accepted Time:
- 2019-04-09 19:00:38
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1662524 | Akcea Therapeutics Inc. | AKCA | Pharmaceutical Preparations (2834) | 472608175 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1703061 | Marc Jeff Goldberg | C/O Akcea Therapeutics, Inc. 22 Boston Wharf Road, 9Th Floor Boston MA 02210 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-04-05 | 30,000 | $6.48 | 32,880 | No | 4 | M | Direct | |
Common Stock | Disposition | 2019-04-05 | 30,000 | $31.71 | 2,880 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2019-04-08 | 20,000 | $6.48 | 22,880 | No | 4 | M | Direct | |
Common Stock | Disposition | 2019-04-08 | 20,000 | $31.72 | 2,880 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2019-04-05 | 30,000 | $0.00 | 30,000 | $6.48 |
Common Stock | Stock Option (right to buy) | Disposition | 2019-04-08 | 20,000 | $0.00 | 20,000 | $6.48 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
322,250 | 2025-12-15 | No | 4 | M | Direct | |
302,250 | 2025-12-15 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The weighted average sale price for the transaction reported was $31.7209, and the range of prices were between $31.71 and $31.85. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- The shares vest as follows: 1/4th of the shares vest one year after January 5, 2015; 1/48th of the shares vest monthly thereafter over the next three years.